Sub menu

Table. Recommendations for MenB vaccine for people with a specified medical condition that increases their risk of invasive meningococcal disease

Age at start of vaccine course	MenB vaccine brand^a	Dose requirements for people with a specified medical condition associated with increased risk of meningococcal disease
6 weeks to 5 months	Bexsero	4 doses (8 weeks between doses; 4th dose at 12 months of age or 8 weeks after 3rd dose, whichever is later)
6–11 months	Bexsero	3 doses (8 weeks between 1st and 2nd doses; 3rd dose at 12 months of age or 8 weeks after 2nd dose, whichever is later)
12 months to 9 years	Bexsero	2 doses (8 weeks between doses)
≥10 years^a	Bexsero	2 doses (8 weeks between doses)
≥10 years^a	Trumenba	3 doses (1 month between 1st and 2nd doses; 6 months between 1st and 3rd doses)
Booster doses for all ages^a	Bexsero	For people with ongoing increased risk of invasive meningococcal disease who completed the primary series at: ≤6 years of age — single booster dose 3 years after completing the primary schedule ≥7 years of age — single booster dose 5 years after completing the primary schedule
Booster doses for all ages^a	Trumenba	For people with ongoing increased risk of invasive meningococcal disease, single booster dose 5 years after completing the primary schedule

a Bexsero and Trumenba are not interchangeable for primary or booster doses.

Page history

Last updated

7 December 2022

Last reviewed

7 December 2022

Printed content may be out of date. For up to date information, always refer to the digital version:

https://immunisationhandbook.health.gov.au/resources/tables/table-recommendations-for-menb-vaccine-for-people-with-a-specified-medical-condition-that-increases-their-risk-of-invasive-meningococcal-disease

Link, share or bookmark directly to this section of the page.